文献速递血栓与止血

利伐沙班与那屈肝素用于肺癌胸部手术后血栓预防的比较:一项随机非劣效性试验

Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
PubMed 文献 · Am J Hematol · 2023-05-04

该随机非劣效性试验纳入403例肺癌胸部手术患者,1:1随机分配至利伐沙班或那屈肝素组,术后12-24小时开始抗凝至出院。主要疗效终点为治疗期间及30天随访内任何静脉血栓栓塞症(VTE),利伐沙班组12.5%(25/200) vs 那屈肝素组17.7%(36/203),绝对风险降低-5.2%(95%CI [-12.2-1.7]),在意向性治疗(ITT)人群显示利伐沙班非劣效。

要点

  • 利伐沙班在肺癌胸部手术后VTE预防中非劣效于那屈肝素。
  • ITT人群VTE发生率:利伐沙班12.5% vs 那屈肝素17.7%,绝对风险降低-5.2%(95%CI [-12.2-1.7])。
  • 治疗期间出血事件两组无显著差异:利伐沙班12.2% vs 那屈肝素7.0%(RR 1.9,95%CI [0.9-3.7],p=.08)。

核心结论

  • 利伐沙班用于肺癌胸部手术后血栓预防非劣效于那屈肝素。

研究设计与样本

  • 随机、非劣效性试验,纳入接受肺癌胸部手术的患者,1:1随机分配至利伐沙班组或那屈肝素组,术后12-24小时开始抗凝并持续至出院。
  • 根据非劣效界值2%、假设利伐沙班组和那屈肝素组VTE发生率分别为6.0%和12.6%,需400例参与者;最终随机403例(ITT人群),其中381例纳入符合方案(PP)人群。

主要发现

  • 主要疗效终点(治疗期间及30天随访内任何VTE)在ITT人群发生率:利伐沙班组12.5%(25/200) vs 那屈肝素组17.7%(36/203),绝对风险降低-5.2%(95%CI [-12.2-1.7]),表明利伐沙班在ITT人群非劣效。
  • PP人群敏感性分析结果相似,证实利伐沙班非劣效。
  • 安全性分析人群中,治疗期间任何出血事件发生率两组无显著差异:利伐沙班12.2% vs 那屈肝素7.0%(RR 1.9,95%CI [0.9-3.7],p=.08)。
  • 大出血发生率:利伐沙班9.7% vs 那屈肝素6.5%(RR 1.6,95%CI [0.9-3.7],p=.24),无显著差异。
  • 非大出血发生率:利伐沙班2.6% vs 那屈肝素0.5%(RR 5.2,95%CI [0.6-45.2],p=.13),无显著差异。

临床怎么用

  • 原文结论为利伐沙班用于肺癌胸部手术后血栓预防非劣效于那屈肝素,未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The benefit of rivaroxaban in thromboprophylaxis after oncologic lung surgery remains unknown. To evaluate the efficacy and safety of rivaroxaban, patients who underwent thoracic surgery for lung cancer were enrolled, and randomly assigned to rivaroxaban or nadroparin groups in a 1:1 ratio; anticoagulants were initiated 12-24 h after surgery and continued until discharge. Four hundred participants were required according to a noninferiority margin of 2%, assuming venous thromboembolism (VTE) occurrence rates of 6.0% and 12.6% for patients in the rivaroxaban and nadroparin groups, respectively. The primary efficacy outcome was any VTE during the treatment and 30-day follow-up periods. The safety outcome was any on-treatment bleeding event. Finally, 403 patients were randomized (intention-to-treat [ITT] population), with 381 included in per-protocol (PP) population. The primary efficacy outcomes occurred in 12.5% (25/200) of the rivaroxaban group and 17.7% (36/203) of the nadroparin group (absolute risk reduction, -5.2%; 95% confidence interval [CI], [-12.2-1.7]), indicating the noninferiority of rivaroxaban in ITT population. Sensitivity analysis was performed in the PP population and yielded similar results, confirming the noninferiority of rivaroxaban. In the safety analysis population, the incidence of any on-treatment bleeding events did not differ significantly between the groups (12.2% for rivaroxaban vs. 7.0% for nadroparin; relative risk [RR], 1.9; 95% CI, [0.9-3.7]; p = .08), including major bleeding (9.7% vs. 6.5%; RR, 1.6 [95% CI, 0.9-3.7]; p = .24), and nonmajor bleeding (2.6% vs. 0.5%; RR, 5.2 [95% CI, 0.6-45.2]; p = .13). Rivaroxaban for thromboprophylaxis after oncologic lung surgery was shown to be noninferior to nadroparin.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhao M, Bao Y, Jiang C, et al. Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. Am J Hematol. 2023. PMID: 37139837. doi:10.1002/ajh.26945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。